Peptomyc
Laura Soucek's work experience includes a role as a Member at referentsfemenins.cat since 2023. Laura has also held various positions at the Vall d'Hebron Institute of Oncology (VHIO) since 2011, including Director of the Preclinical and Translational Research Program and Head of Models of Cancer Therapies Laboratory. In 2014, they became a Research Professor at ICREA and founded Peptomyc, where they currently serve as the Chief Executive Officer. Prior to that, they were an Associate Professor at the Universitat Autònoma de Barcelona. Laura has also worked as a Research Assistant Molecular Biologist at UCSF, Comprehensive Cancer Center from 2006 to 2011, and as a Postdoc at UCSF from 2001 to 2006. Laura began their career as a Molecular Biologist at the Istituto di Biologia e Patologia Molecolari in Rome from 2000 to 2001, and they were a PhD student in Genetics and Molecular Biology at the University La Sapienza in Rome from 1997 to 2001.
Laura Soucek's education history includes the following:
- In 2020, they completed "The Pharma Business Development" Course at CELforPharma, focusing on Business Development.
- In 2018, they attended EBD Academy for an Advanced Business Development Course, also in the field of Business Development.
- From 1997 to 2000, they pursued their PhD at Sapienza Università di Roma, specializing in Genetics and Molecular Biology.
- Between 1991 and 1996, they obtained a University Degree from Sapienza Università di Roma, with a specialization in Biology, specifically Biotechnology.
- From 1986 to 1991, Laura attended Liceo Classico A. Mancinelli and completed their Maturità Classica.
- Additionally, Laura has taken The Pharmaceutical Out-licensing Course at CELforPharma, though the specific dates are not provided.
This person is not in any teams
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.